According to reports from the international diabetes arena, shares in San Diego based Amylin Pharmaceuticals Inc. dropped to a two-year low this week. The slide in shares in the diabetes company is a further representation of declines in the biotechnology sector.
However, the horizon is not bleak for Amylin. Their experimental diabetes drug exenatide LAR is likely to dominate the drug market, and could fuel the growth of the company . The drug is a long-acting release diabetes treatment agent, and is taken by diabetics once a week.
Amylin are in a production partnership for the drug with Alkermes Inc. and Eli Lilly, the drug giant. The drug could potentially replace Byetta, the current Amylin diabetes drug. Early-stage clinical trials indicate that exenatide is more effective at controlling blood glucose .
A number of exciting new diabetes drug products are likely to hit the market in the next couple of years.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…